News

Rituximab seen as safe, effective in treating MuSK-positive MG

Rituximab can safely and effectively control myasthenia gravis (MG) in patients with antibodies against muscle-specific kinase or MuSK, according to a new analysis. “Rituximab has demonstrated effectiveness and safety as a treatment for anti-MuSK MG. It has the potential to help patients with any baseline severity, especially those…

MDA Clinical & Scientific Conference starts on March 16

Note: This story has been updated March 6, 2025, to correct a quote from Mindy Henderson, MDA vice president of disability outreach and empowerment. The Muscular Dystrophy Association (MDA) is once again hosting its annual gathering, the MDA Clinical & Scientific Conference. The 2025 event will take place…

Myasthenic crisis tied to high lactic acid levels after thymectomy

High levels of lactic acid in the bloodstream immediately after surgery to remove the thymus gland were associated with an increased risk of postoperative myasthenic crisis, or POMC, among people with myasthenia gravis (MG), a study reveals. “These findings offer valuable insights for clinical decision-making and monitoring of prognosis…

Ultomiris successfully treats woman with thymoma-associated MG: Case

A 39-year-old woman with severe myasthenia gravis (MG) associated with a thymoma, a thymus tumor, responded favorably to treatment with Ultomiris (ravulizumab), according to a case study from clinicians in Greece. The treatment successfully managed the woman’s rapidly evolving symptoms in the acute setting. The patient later underwent…